AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis after left colectomy
Number of subjects: 0
Study 2064291 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomoses after left colectomy
Number of subjects: 0
Study 2064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 0
Study 2064291 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomosis
Number of subjects: 0
Study 6340552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 2 mg/kg b.wt.
Number of subjects: 24
Study 6340552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 4 mg/kg b.wt.
Number of subjects: 24
Study 6340552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6340552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (both doses)
Number of subjects: 24
Study 31875000 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil based therapy
Number of subjects: 176
Study 31875000 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-C3 (pro-peptide of type III collagen)
Number of subjects: 176
Study 31875000 — intervention group
Group type: EXPERIMENTAL
Intervention: C3M (degradation of type III collagen) and PRO-C3 ratio
Number of subjects: 176
Study 31875000 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-C3 (adjusted for CA19-9 and clinical covariates)
Number of subjects: 176
Study 29417793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement (biotin, probiotic, vitamin E, zinc, nicotinamide; males: beta sitosterol and Boswellia serrata; females: myo‐inositol and folic acid) and topical cream device (verbascoside, Ocimum gratissimum, salicylic acid, gluconolactone, complex alpha‐hydroxy acids)
Number of subjects: 0
Study 29417793 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream device (verbascoside, Ocimum gratissimum, salicylic acid, gluconolactone, complex alpha‐hydroxy acids)
Number of subjects: 0
Study 29417793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement
Number of subjects: 0
Study 29417793 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25856160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.45 mg/day) with intermittent progesterone (200 mg/day for 12 days a month)
Number of subjects: 117
Study 25856160 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (50 µg/day) with intermittent progesterone (200 mg/day for 12 days a month)
Number of subjects: 117
Study 25856160 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 117
Study 25367551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg + normal saline 0.05 ml/kg (DEX)
Number of subjects: 400
Study 25367551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg + normal saline 0.05 ml/kg (KET)
Number of subjects: 400
Study 25367551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg + dexmedetomidine 0.5 μg/kg (KETODEX)
Number of subjects: 400
Study 25367551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (volume-matched normal saline 0.15 mL/kg + normal saline 0.05 mL/kg)
Number of subjects: 400
Study 22640724 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance responses in a modified Stroop task
Number of subjects: 0
Study 22640724 — intervention group
Group type: COMPARATOR
Intervention: Approach responses in a modified Stroop task
Number of subjects: 0
Study 20500877 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol succinate
Number of subjects: 24
Study 20500877 — intervention group
Group type: COMPARATOR
Intervention: 50 mg carvedilol
Number of subjects: 24
Study 17980941 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental muscle pain
Number of subjects: 20
Study 17980941 — intervention group
Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 20
Study 15950631 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogest 200 (200 mg vaginal capsules, three times per day)
Number of subjects: 430
Study 15950631 — intervention group
Group type: COMPARATOR
Intervention: Crinone 8% (vaginal gel, two times per day)
Number of subjects: 430
Study 15950631 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogest 200
Number of subjects: 430
Study 15950631 — intervention group
Group type: COMPARATOR
Intervention: Crinone 8%
Number of subjects: 430
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs) such as oxcarbazepine, levetiracetam, zonisamide, lamotrigine, and topiramate
Number of subjects: 0
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine or topiramate
Number of subjects: 0
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide and levetiracetam
Number of subjects: 0
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide, lamotrigine, topiramate, and levetiracetam
Number of subjects: 0
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of new AEDs
Number of subjects: 0
Study 11474769 — intervention group
Group type: EXPERIMENTAL
Intervention: First therapy given to newly diagnosed patients
Number of subjects: 0
Study 9725503 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (Rilutek)
Number of subjects: 0
Study 9725503 — intervention group
Group type: EXPERIMENTAL
Intervention: Proc MIXED (SAS)
Number of subjects: 0
Study 8306268 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMU-4 99mTc-Fab' fragments (1 mg, 19.3 mCi average)
Number of subjects: 35
Study 8306268 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMU-4 99mTc-Fab' fragments
Number of subjects: 35
Study 2471472 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg with procainamide dose after 100 mg twice a day for 2 days)
Number of subjects: 10
Study 2471472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 790550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg/day)
Number of subjects: 137
Study 790550 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 137
Study 790550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (200 mg/day)
Number of subjects: 137
Study 790550 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone (300 mg/day)
Number of subjects: 137
Study 30501977 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Relearning Program
Number of subjects: 488
Study 30501977 — intervention group
Group type: COMPARATOR
Intervention: Bobath Approach
Number of subjects: 488
Study 28091641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Number of subjects: 225
Study 28091641 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog therapy with pomegranate extract
Number of subjects: 225
Study 28091641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 26586495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity exercise (LIG; n=44; 60-65% VO2peak, 50-65% 1RM)
Number of subjects: 159
Study 26586495 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity exercise (HIG; n=40; 75-80% VO2peak, 65-80% 1RM)
Number of subjects: 159
Study 26586495 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 159
Study 24585202 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 24585202 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0
Study 24585202 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (add-on to metformin + sulfonylurea)
Number of subjects: 0
Study 24585202 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (add-on to metformin + sulfonylurea)
Number of subjects: 0
Study 24585202 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study 21829006 — intervention group
Group type: EXPERIMENTAL
Intervention: IM peribulbar injection
Number of subjects: 200
Study 21829006 — intervention group
Group type: COMPARATOR
Intervention: IT peribulbar injection
Number of subjects: 200
Study 20014598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 19.5 mg with fentanyl 20 microg (group R)
Number of subjects: 52
Study 20014598 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 13 mg with fentanyl 20 microg (group B)
Number of subjects: 52
Study 17563982 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneopelotherapy (sulfide mud)
Number of subjects: 60
Study 17563982 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneopelotherapy (sulfide mud) plus Transcranial Electro-stimulation (TCE)
Number of subjects: 60
Study 15638236 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered as three infusions at 0, 2, and 6 weeks, then every 8 weeks
Number of subjects: 20
Study 15638236 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (0.7-1 mg/kg) daily for one week followed by tapering regimen
Number of subjects: 20
Study 11442865 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal tramadol 2 mg.kg‐1 (group T)
Number of subjects: 0
Study 11442865 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal morphine 0.03 mg.kg‐1 (group M)
Number of subjects: 0
Study 11442865 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) received morphine sulphate 0.03 mg.kg‐1 at the end of surgery, caudally
Number of subjects: 0
Study 11442865 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal morphine or tramadol (presurgical)
Number of subjects: 0
Study 11442865 — intervention group
Group type: COMPARATOR
Intervention: Caudal morphine (postsurgical)
Number of subjects: 0
Study 9007773 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoinertial trunk extensor strength
Number of subjects: 28
Study 9007773 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric trunk extensor strength
Number of subjects: 28
Study 9007773 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 28
Study 9007773 — intervention group
Group type: EXPERIMENTAL
Intervention: Torso length
Number of subjects: 28
Study 9007773 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional testing
Number of subjects: 28
Study 8496640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐Shah grommet
Number of subjects: 116
Study 8496640 — intervention group
Group type: COMPARATOR
Intervention: Shah grommet
Number of subjects: 116
Study 2896653 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 16
Study 2896653 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 16
Study 2896653 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 16
Study 2896653 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 16
Study 2896653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30019843 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon catheters (PEB)
Number of subjects: 136
Study 30019843 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 136
Study 26835876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 87
Study 24102986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control arm
Number of subjects: 693
Study 24102986 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 693
Study 22623385 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group with untreated mushrooms providing 0.85 μg/d ergocalciferol
Number of subjects: 38
Study 22623385 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 group with UV-treated mushrooms providing 8.8 μg/d ergocalciferol
Number of subjects: 38
Study 22623385 — intervention group
Group type: EXPERIMENTAL
Intervention: M2 group with UV-treated mushrooms providing 17.1 μg/d ergocalciferol
Number of subjects: 38
Study 22623385 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement (S) group with purified ergocalciferol plus untreated mushrooms providing a total of 28.2 μg/d
Number of subjects: 38
Study 20797476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (salmon) diet
Number of subjects: 92
Study 20797476 — intervention group
Group type: COMPARATOR
Intervention: Freshwater fish diet
Number of subjects: 92
Study 20797476 — intervention group
Group type: COMPARATOR
Intervention: Pork/chicken/beef diet
Number of subjects: 92
Study 18580877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg in divided b.i.d. dose
Number of subjects: 188
Study 18580877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 16617380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (group D)
Number of subjects: 158
Study 16617380 — intervention group
Group type: COMPARATOR
Intervention: Anthracyclines only (group C)
Number of subjects: 158
Study 14565629 — intervention group
Group type: EXPERIMENTAL
Intervention: New ultrasonic method for direct assessment of maximal varicose vein diameter (VVD)
Number of subjects: 0
Study 14565629 — intervention group
Group type: EXPERIMENTAL
Intervention: New ultrasonic method for detecting changes in VVD induced by pharmacologic treatment
Number of subjects: 0
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (specifically diuretics)
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antihypertensive drugs
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: High 2-h OGTT value (>9.0 mmol/l)
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: High fasting insulin level (>12.0 mU/l)
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglyceride level (>/=1.3 mmol/l)
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI (>/=28.0 kg/m(2))
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (BP 160/95 or antihypertensive medication)
Number of subjects: 207
Study 11106838 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 207
Study 11106838 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h OGTT concentration
Number of subjects: 207
Study 8797128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg (increased to 40 mg after 8 weeks, average 25.6 mg)
Number of subjects: 195
Study 8797128 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg (increased to 20 mg after 8 weeks, average 12.9 mg)
Number of subjects: 195
Study 8797128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 195
Study 8797128 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 195
Study 8427433 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC (meperidine 2 mg/kg + promethazine 1 mg/kg + chlorpromazine)
Number of subjects: 87
Study 8427433 — intervention group
Group type: COMPARATOR
Intervention: MP (meperidine 2 mg/kg + promethazine 1 mg/kg)
Number of subjects: 87
Study 3592208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg ketamine intravenously
Number of subjects: 20
Study 3592208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine intravenously
Number of subjects: 20
Study 30343315 — intervention group
Group type: EXPERIMENTAL
Intervention: 32°C
Number of subjects: 150
Study 26806397 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan with leucovorin/5-fluorouracil)
Number of subjects: 55
Study 26806397 — intervention group
Group type: EXPERIMENTAL
Intervention: FUPEP (PEP02 with leucovorin/5-fluorouracil)
Number of subjects: 55
Study 26806397 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 55
Study 26806397 — intervention group
Group type: EXPERIMENTAL
Intervention: FUPEP
Number of subjects: 55
Study 25027018 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI-recovery group
Number of subjects: 4315
Study 25027018 — intervention group
Group type: COMPARATOR
Intervention: Non-AKI group
Number of subjects: 4315
Study 25027018 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI alone (without diabetes)
Number of subjects: 4315
Study 25027018 — intervention group
Group type: COMPARATOR
Intervention: Diabetes alone (without AKI)
Number of subjects: 4315
Study 22853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity (SBS‐PA) - 10 min structured PA routines, twice daily, followed by 20 min unstructured playtime
Number of subjects: 315
Study 22853642 — intervention group
Group type: COMPARATOR
Intervention: Unstructured physical activity (UPA) - 30 min supervised unstructured free playtime, twice daily
Number of subjects: 315
Study 19534290 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs)
Number of subjects: 20
Study 19534290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar-recorded SEPs
Number of subjects: 20
Study 19534290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory nerve stimulated SEPs
Number of subjects: 20
Study 19534290 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrophysiologic methods (needle EMG, late responses, nerve conduction studies)
Number of subjects: 20
Study 16835746 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (ASCT)
Number of subjects: 35
Study 15718881 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 93
Study 15718881 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 93
Study 12546253 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitated Assertive Community Treatment (ACT) program
Number of subjects: 500
Study 12546253 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 500
Study 9506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated soft drink (CC)
Number of subjects: 8
Study 9506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Na+ mineral water (MW)
Number of subjects: 8
Study 9506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate‐electrolyte solution (CES)
Number of subjects: 8
Study 8568707 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal laser therapy in Group I
Number of subjects: 84
Study 8568707 — intervention group
Group type: COMPARATOR
Intervention: Control group in Group I
Number of subjects: 84
Study 8568707 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal and scatter laser therapy in Group II
Number of subjects: 84
Study 3219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 250 micrograms + ethinyl estradiol 50 micrograms (Neogynon)
Number of subjects: 407
Study 3219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 250 micrograms + ethinyl estradiol 30 micrograms (Eugynon 30)
Number of subjects: 407
Study 3219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms + ethinyl estradiol 30 micrograms (Microgynon)
Number of subjects: 407
Study 3219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1 mg + ethinyl estradiol 50 micrograms (Minovlar)
Number of subjects: 407
Study 3219852 — intervention group
Group type: COMPARATOR
Intervention: Control group (CuT220c IUD users)
Number of subjects: 407
Study 3219852 — intervention group
Group type: EXPERIMENTAL
Intervention: All OC users
Number of subjects: 407
Study 31888365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (fracture fixation or humeral head replacement)
Number of subjects: 250
Study 28802628 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 420
Study 28802628 — intervention group
Group type: EXPERIMENTAL
Intervention: Housework physical activity (HPA)
Number of subjects: 420
Study 28802628 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening physical activity (GPA)
Number of subjects: 420
Study 28802628 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 420
Study 27355261 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid regimen (LIB) - crystalloid 12 mL/kg/h
Number of subjects: 330
Study 27355261 — intervention group
Group type: COMPARATOR
Intervention: Restricted fluid regimen (RES) - crystalloid 6 mL/kg/h
Number of subjects: 330
Study 25742370 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise via Negative Eccentric Work (RENEW)
Number of subjects: 42
Study 25742370 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group (Active Control)
Number of subjects: 42
Study 23506716 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic supracervical hysterectomy (n = 70)
Number of subjects: 140
Study 23506716 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy with excision of the endocervix in a reverse cone pattern (n = 70)
Number of subjects: 140
Study 21091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation
Number of subjects: 0
Study 21091245 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 19178101 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing (Test group A, n = 156)
Number of subjects: 411
Study 19178101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel applications (Test group B, n = 118)
Number of subjects: 411
Study 19178101 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 137)
Number of subjects: 411
Study 17078213 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 43
Study 17078213 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg)
Number of subjects: 43
Study 14599998 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year exercise-centered health-promoting programme
Number of subjects: 245
Study 14599998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 245